Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
First Claim
Patent Images
1. An oral dosage form comprising (i) an controlled release core;
- and (ii) an immediate release gelatin capsule around the controlled release core, wherein the controlled released core comprises at least one therapeutically active agent and at least one controlled release material; and
wherein the immediate release gelatin capsule comprises at least one therapeutically active agent.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.
280 Citations
104 Claims
-
1. An oral dosage form comprising (i) an controlled release core;
- and (ii) an immediate release gelatin capsule around the controlled release core, wherein the controlled released core comprises at least one therapeutically active agent and at least one controlled release material; and
wherein the immediate release gelatin capsule comprises at least one therapeutically active agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 103, 104)
- and (ii) an immediate release gelatin capsule around the controlled release core, wherein the controlled released core comprises at least one therapeutically active agent and at least one controlled release material; and
-
93. A method of making an oral dosage form comprising:
-
(i) preparing a controlled release core, wherein the controlled released core comprises at least one therapeutically active agent and at least one controlled release material; and
(ii) an immediate release gelatin capsule around the controlled release core, wherein the immediate release gelatin capsule coating comprises at least one therapeutically active agent. - View Dependent Claims (94)
-
-
95. A method of selectively enhancing analgesic potency of an opioid agonist or attenuating an adverse side effect of the opioid agonist in a human subject comprising:
-
(i) administering to the human subject an oral dosage form comprising;
(a) a controlled release core; and
(b) an immediate release gelatin capsule around the controlled release core;
wherein the controlled released core comprises at least one opioid agonist and at least one controlled release material;
wherein the immediate release gelatin capsule coating comprises at least one opioid antagonist, and wherein the antagonist enhances the analgesic potency of the opioid agonist or attenuates an adverse side effect of the agonist in the human subject. - View Dependent Claims (96)
-
-
97. A method of selectively enhancing analgesic potency of an opioid agonist or attenuating an adverse side effect of the opioid agonist in a human subject comprising:
-
(i) administering to the human subject an oral dosage form comprising;
(a) a controlled release core; and
(b) an immediate release gelatin capsule around the controlled release core;
wherein the controlled released core comprises at least one opioid agonist and at least one controlled release material;
wherein the immediate release gelatin capsule comprises at least one opioid agonist and at least one opioid antagonist, and wherein the antagonist enhances the analgesic potency of the opioid agonist or attenuates an adverse side effect of the agonist in the human subject. - View Dependent Claims (98)
-
-
99. A method of selectively enhancing analgesic potency of an opioid agonist or attenuating an adverse side effect of the opioid agonist in a human subject comprising:
-
(i) administering to the human subject an oral dosage form comprising;
(a) a controlled release core; and
(b) an immediate release gelatin capsule coating around the controlled release core;
wherein the controlled released core comprises at least one opioid agonist, at least one opioid antagonist, and at least one controlled release material;
wherein the immediate release gelatin capsule comprises at least one opioid agonist, and wherein the antagonist enhances the analgesic potency of the opioid agonist or attenuates an adverse side effect of the agonist in the human subject. - View Dependent Claims (100)
-
-
101. A method of selectively enhancing analgesic potency of an opioid agonist or attenuating an adverse side effect of the opioid agonist in a human subject comprising:
-
(i) administering to the human subject an oral dosage form comprising;
(a) a controlled release core; and
(b) an immediate release gelatin capsule around the controlled release core;
wherein the controlled released core comprises at least one opioid agonist, at least one opioid antagonist, and at least one controlled release material;
wherein the immediate release gelatin capsule comprises at least one opioid agonist and at least one opioid antagonist, and wherein the antagonist enhances the analgesic potency of the opioid agonist or attenuates an adverse side effect of the agonist in the human subject. - View Dependent Claims (102)
-
Specification